rofecoxib has been researched along with Hemangioendothelioma in 1 studies
Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Six patients with advanced and pretreated but progressive, malignant vascular tumors (5 angiosarcomas and 1 hemangioendothelioma) received a combination of pioglitazone (45 mg per day orally) plus rofecoxib (25 mg per day orally) and, after 14 days, trofosfamide (3 x 50 mg per day orally)." | 5.10 | Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Hafner, C; Jauch, KW; Landthaler, M; Reichle, A; Vogt, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogt, T | 1 |
| Hafner, C | 1 |
| Bross, K | 1 |
| Bataille, F | 1 |
| Jauch, KW | 1 |
| Berand, A | 1 |
| Landthaler, M | 1 |
| Andreesen, R | 1 |
| Reichle, A | 1 |
1 trial available for rofecoxib and Hemangioendothelioma
| Article | Year |
|---|---|
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2003 |